Aizon, the AI SaaS provider transforming pharmaceutical manufacturing, announced today the closing of a $20 million Series C funding round led by NewVale Capital. Existing investors Atlantic Bridge, Crosslink Capital, and Uncork Capital also participated. This investment reinforces Aizon's position as a leader in AI-enhanced pharmaceutical manufacturing and will propel the launch of its next-generation eBR solution.

Aizon's advanced predictive analytics and AI technologies empower pharmaceutical manufacturers with unparalleled insights and decision-making capabilities. By prioritizing quality and compliance, Aizon ensures GMP processes adhere to rigorous standards, driving optimization, cost reduction, and predictive maintenance.

"This investment validates the success of our platform and accelerates our strategic roadmap," said Pep Gubau, Aizon CEO and co-founder. "With this capital, we will launch our eBR solution in Q3 2024, further demonstrating our commitment to innovation and customer empowerment."

Todd Holmes, managing partner at NewVale Capital, commented, "Aizon is poised to redefine pharmaceutical manufacturing. We're excited to support their growth as they continue transforming the industry with their AI-driven solutions."